Lincomycin

Summary

Lincomycin (CHEMBL1447) is an approved small-molecule antimicrobial agent (ATC J01FF02); indicated across 3 conditions including bacterial infectious disease and multiple sclerosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01FF02
• Indications: 3 conditions
• Clinical trials: 1
• Chemistry: 406.5 Da · C18H34N2O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1447
Name	Lincomycin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3000540
ChEBI	CHEBI:6472
ATC	J01FF02
Molecular formula	C18H34N2O6S
Molecular weight	406.5
InChIKey	OJMMVQQUTAEWLP-KIDUDLJLSA-N

SMILES: CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O

IUPAC name: (2S,4R)-N-[(1R,2R)-2-hydroxy-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide

ChEBI definition: A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.

Pharmacological roles (ChEBI): antimicrobial agent.

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: Lincolnensin, Lincomicina, Lincomycin, Lincomycine, U-10,149, U-10149, lincomycin, lincomycin A, LINCOMYCIN, LINCOMYCINE

Parent form; salt/anhydrous children: CHEMBL3989551, CHEMBL4075711

Patent coverage: 10,217 distinct patent families (33,659 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Albumin.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
multiple sclerosis	4	MONDO:0005301	MONDO:0005301
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01058824	PHASE1	COMPLETED	Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).